Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are
revolutionizing oncology and haematology practice. With these and other immunotherapies …

The stimulator of interferon genes (STING) cellular signaling pathway is a promising target
for cancer immunotherapy. Activation of the intracellular STING protein triggers the …

Therapeutic targeting of the immune system in cancer is now a clinical reality and marked
successes have been achieved, most notably through the use of checkpoint blockade …

In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently
seen as a potential therapeutic option for patients with cancer who do not respond or fail to …

Local immunotherapy ideally stimulates immune responses against tumors while avoiding
toxicities associated with systemic administration. Current strategies for tumor-targeted …

Purpose: SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle 1917
(EcN) engineered to produce cyclic dinucleotides under hypoxia, leading to STimulator of …

The stimulator of IFN genes (STING) signaling pathway is a critical link between innate and
adaptive immunity and induces antitumor immune responses. STING is expressed in …

The clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-
associated protein (Cas) systems are efficient and versatile gene editing tools, which offer …

Immune checkpoint inhibitors (ICIs) can reinvigorate T cells to eradicate tumor cells,
showing great potential in combating various types of tumors. We propose a delivery …

Cancer radio-immunotherapy, integrating external/internal radiation therapy with immuno-
oncology treatments, emerges in the current management of cancer. A growing number of …